Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Open-Label Extension Study to Evaluate the Efficacy and Safety of MHB018A Injection in Subjects With Thyroid Eye Disease

NCT07262476 is registered in ClinicalTrials.gov with Minghui Pharmaceutical (Hangzhou) Ltd as lead sponsor.

NCT NCT07262476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07262476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Open-Label Extension Study to Evaluate the Efficacy and Safety of MHB018A Injection in Subjects With Thyroid Eye Disease
Lead sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
January 9, 2026
Completion date
January 31, 2030
Enrollment
258 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease (ted)